Log In
Print
BCIQ
Print
Print this Print this
 

pacritinib (ONX 0803, SB1518)

  Manage Alerts
Collapse Summary General Information
Company CTI BioPharma Corp.
DescriptionOrally available dual inhibitor of Janus kinase-2 (JAK-2) and FMS-like tyrosine kinase 3 (FLT3; CD135)
Molecular Target Janus kinase-2 (JAK-2) ; FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of ActionJanus kinase-2 (JAK-2) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$912.0M

$45.0M

$959.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today